Brave Bio, a biotech startup, has filed for an initial public offering seeking $319 million. The deal is backed by Andreessen Horowitz (a16z), the venture capital giant best known for its crypto bets. The move signals a16z's growing appetite for life sciences investments.
IPO details
The company didn't specify a share price range or the number of shares to be sold in the filing. Brave Bio is expected to list on the Nasdaq under the ticker symbol BRAV. The $319 million target is based on a placeholder amount used to calculate registration fees.
a16z's expanding focus
Andreessen Horowitz has been a dominant force in crypto and web3, backing companies like Coinbase and Solana. But this IPO shows the firm is willing to place big bets outside that lane. Brave Bio is developing treatments for rare diseases, and a16z's involvement suggests the firm sees a path to commercial returns in biotech.
The IPO is still subject to SEC review. Brave Bio hasn't set a date for pricing. The company will need to convince public market investors that its pipeline is worth the valuation implied by the $319 million raise.
